前列腺癌术前放疗的1期初步研究:远期毒性与肿瘤学结局
2001至2004年开展的1期初步研究评估短期术前放疗(PreORT)用于不利中危及高危局限性前列腺癌的长期毒性与肿瘤学结局。14例完成25 Gy/5次前列腺照射后14天内行根治性前列腺切除术,中位随访12.2年,晚期泌尿生殖毒性常见(G2 13.3%、G3 40%),晚期胃肠道毒性少见,生化复发53.3%、转移复发40%。
要点
- 晚期泌尿生殖毒性常见:G2 13.3%、G3 40%,无G4至G5。
- 晚期胃肠道毒性少见,仅1例(6.7%)发生一过性G2直肠炎。
- 末次随访时生化复发8例(53.3%)、转移复发6例(40%)。
核心结论
- 高危前列腺癌患者使用PreORT与意料之外的高晚期泌尿生殖毒性发生率相关。
- 作者认为未来研究根治性前列腺切除术前放疗作用时必须谨慎选择放疗技术和剂量方案。
- 作者强调长期随访数据对充分确定PreORT治疗局限性疾病的治疗指数至关重要。
研究设计与样本
- 2001至2004年开展的单臂1期初步研究。
- 纳入组织学证实的前列腺癌、cT1-T2N0M0、前列腺特异性抗原>15至35 ng/mL(不限Gleason评分)或前列腺特异性抗原10至15 ng/mL且Gleason评分≥7的患者。
- 方案为前列腺仅照射25 Gy分5次连续每日(每次5 Gy),放疗完成后14天内行根治性前列腺切除术。
- 主要结局为术中并发症及晚期泌尿生殖毒性和胃肠道毒性。
- 共15例入组,14例完成PreORT及根治性前列腺切除术,其中13例行双侧淋巴结清扫。
主要发现
- 中位随访12.2年(范围6.7至16.3年)。
- 晚期泌尿生殖毒性:2例(13.3%)发生G2毒性,6例(40%)发生G3毒性,无G4至G5晚期泌尿生殖毒性。
- 晚期胃肠道毒性少见,仅1例(6.7%)发生一过性G2直肠炎。
- 末次随访时8例(53.3%)发生生化复发,6例(40%)发生转移复发。
临床怎么用
- 作者认为根治性前列腺切除术前放疗的未来研究必须谨慎选择放疗技术和剂量方案。
- 作者强调长期随访数据对充分确定PreORT治疗局限性疾病的治疗指数至关重要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Neoadjuvant radiation therapy (RT) improves disease control in various cancers and has become an established oncologic treatment strategy. During 2001 to 2004, we conducted a phase 1 pilot study assessing the role of short-course preoperative RT (PreORT) for men with unfavorable intermediate- and high-risk localized prostate cancer. Herein, we present long-term follow-up toxicity and oncologic outcomes. METHODS AND MATERIALS: Eligible patients had histologically proven prostate cancer, cT1-T2N0M0 disease, prostate-specific antigen >15 to 35 ng/mL regardless of Gleason score, or prostate-specific antigen 10 to 15 ng/mL with Gleason score ≥7. Patients received 25 Gy in 5 consecutive daily fractions (5 Gy per fraction) to the prostate only, followed by radical prostatectomy within 14 days after RT completion. Primary outcomes were intraoperative morbidity and late genitourinary (GU) and gastrointestinal toxicities. RESULTS: In total, 15 patients were enrolled; 14 patients completed PreORT followed by radical prostatectomy, which also included bilateral lymph node dissections in 13 cases. Median follow-up was 12.2 years (range, 6.7-16.3). Late GU toxicity was common, with 2 patients (13.3%) experiencing G2 toxicity and 6 patients (40%) G3 toxicity. There were no patients with G4 to G5 late GU toxicity. Late gastrointestinal toxicity was infrequent, with only 1 patient (6.7%) experiencing transient G2 proctitis. At last follow-up, 8 (53.3%) and 6 (40%) patients experienced biochemical and metastatic disease recurrence, respectively. CONCLUSIONS: The use of PreORT in men with high-risk prostate cancer is associated with unexpected high rates of late GU toxicity. Future studies examining the role of RT preradical prostatectomy must cautiously select RT technique and dose schedule. Importantly, long-term follow-up data are essential to fully determine the therapeutic index of PreORT in the management of localized disease.
引用
- Glicksman R, Sanmamed N, Thoms J, et al. A Phase 1 Pilot Study of Preoperative Radiation Therapy for Prostate Cancer: Long-Term Toxicity and Oncologic Outcomes. Int J Radiat Oncol Biol Phys. 2019. PMID: 30625410. doi:10.1016/j.ijrobp.2018.12.054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。